QuikRead go easy CRP supports antibiotic stewardship in neonates.
Neonatal infections remain one of the leading causes of mortality and long-term complications, particularly among premature and very low birthweight infants. Diagnosing these infections is notoriously difficult—especially in low-resource settings—often resulting in prolonged and unnecessary antibiotic use. This not only exposes vulnerable infants to potential side effects but also fuels the global crisis of antibiotic resistance.
But what if there were a way to make faster, more accurate decisions at the bedside?
A Promising Solution: CRP Point-of-Care Testing
A recent prospective observational study published in BMC Pediatrics (Lloyd et al., 2025) evaluated a novel clinical decision-making tool that integrates clinical signs with C-reactive protein (CRP) point-of-care testing (POCT). At the heart of this tool is Aidian’s QuikRead go easy CRP, a rapid and reliable POCT device designed to support clinicians in managing suspected healthcare-associated infections (HAIs) in very low birthweight neonates.
The results were compelling:
- 98.3% sensitivity and 97.8% specificity in identifying infections.
- 2-day reduction in overall antibiotic treatment duration.
- 40.7% of antibiotic courses could potentially have been safely avoided.
These findings suggest that combining clinical scoring with CRP POCT can significantly enhance diagnostic accuracy and reduce unnecessary antibiotic exposure.
In neonatal units—especially those in low-resource settings—access to comprehensive diagnostic tools is often limited. The QuikRead go easy CRP offers a practical, scalable solution that empowers healthcare providers to:
- Make faster, evidence-based decisions.
- Minimise unnecessary antibiotic use.
- Improve patient outcomes while supporting global antibiotic stewardship efforts.
The integration of CRP POCT into neonatal care protocols represents a major step forward in the fight against antibiotic resistance. Tools like QuikRead go easy CRP not only enhance clinical confidence but also ensure that the most vulnerable patients receive the right treatment at the right time.
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
